Comparative Pharmacology
Head-to-head clinical analysis: CATAPRES TTS 1 versus CATAPRES TTS 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAPRES TTS 1 versus CATAPRES TTS 3.
CATAPRES-TTS-1 vs CATAPRES-TTS-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic agonist that reduces sympathetic outflow from the CNS, leading to decreased peripheral vascular resistance and blood pressure.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Clonidine transdermal system 0.1 mg/24 hours applied to intact skin on upper arm or chest once every 7 days. Titrate based on response, maximum 0.3 mg/24 hours.
Transdermal patch: 0.3 mg/day applied once every 7 days; initial dose 0.1 mg/day, titrate weekly by 0.1 mg/day increments to desired response.
None Documented
None Documented
12-16 hours; may be prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life is 12-16 hours after oral administration; with transdermal delivery, the effective half-life is prolonged to 20-40 hours due to continued absorption from the skin depot. In renal impairment, half-life may extend to 40 hours or longer.
Renal: 40-60% unchanged; biliary/fecal: ~20% as metabolites; remainder metabolized.
Approximately 40-60% of the absorbed dose is excreted unchanged in urine. About 20-30% is eliminated as metabolites via bile and feces. Renal clearance accounts for 50-60% of total clearance.
Category C
Category C
Central Alpha-Agonist
Central Alpha-Agonist